Vaxart Inc., a biotechnology company focused on the development of oral vaccines, said it received $3.3 million in new funding.

San Francisco-based Vaxart said the round was led by San Jose-based Quantum Technology Partners and Palo Alto-based Life Science Angels.

Other investors include Bay Partners and Sand Hill Angels, which both have offices in Menlo Park.

Vaxart also said it was awarded (under its former name of West Coast Biologicals) a National Institutes of Health SBIR grant of $600,000 for development of the company’s platform technology. Vaxart will use the new capital to support late-stage preclinical testing for its first product, a vaccine for avian flu.

– San Jose Business Journal

Tags: Vaxart